SynthesisESMO open2023
Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis.
Synthesis in ESMO open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Prognosis of Pregnancy-Associated Breast Cancer: A Systematic Review of Contemporary Observational Studies.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Fertility preservation in breast cancer patients: a systematic review and summary of current evidence and recommendations.Breast cancer research and treatment · 2026Pooled it
- Cancer outcomes of pregnancy after diagnosis of breast cancer in premenopausal women: an updated systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Review
- Assisted Reproductive Technology in Breast and Gynecologic Malignancies: Cancer Risk, Fertility Preservation, and Post-Treatment Reproductive Outcomes.Journal of clinical medicine · 2026Review
- Cancer During Pregnancy: Navigating Clinical and Research Challenges.Current oncology (Toronto, Ont.) · 2026Review
- Early-Stage Breast Cancer in Women Younger Than 50 Years: Comparing American Joint Committee on Cancer Anatomic and Prognostic Stages With Partitioning Around Medoids Clusters in SEER Data.JCO clinical cancer informatics · 2026Article
- Impact of the interruption of tamoxifen for pregnancy on the recurrence and survival outcomes among young women with breast cancer.Breast (Edinburgh, Scotland) · 2026Article
- Breast Cancer Surgical Risk Reduction, Fertility and Fertility Preservation for Current Breast Cancer Reports.Current breast cancer reports · 2026Review
- Fertility preservation and reproductive outcomes in young women with breast and gynecological cancers: a new challenge for the clinician.Frontiers in oncology · 2026Review
- Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies.Human reproduction (Oxford, England) · 2025Review
- Oncofertility Barriers in Nurses Caring for Women with Breast Cancer.Scientific reports · 2025Article
- Estrogens and breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Review
- Pregnancy after breast cancer treatment in young patients.Frontiers in oncology · 2025Article
- Fertility preservation in young patients with breast cancer: insights from the Gemme Dormienti network.Therapeutic advances in medical oncology · 2025Article
- Pregnancy after breast cancer: latest evidence and practical considerations.Therapeutic advances in medical oncology · 2025Review
- Early breast cancer in youngTherapeutic advances in medical oncology · 2025Review
- Ovarian stimulation with letrozole in nulliparous young women with relapsing early-stage serous borderline ovarian tumors.Gynecologic oncology reports · 2024Article
- Adverse Obstetric Outcomes after Breast Cancer Diagnosis: An Observational Database Study in Germany.Cancers · 2024Article
- Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?ESMO open · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 10 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite increasing evidence on the safety of pregnancy after anticancer treatments in breast cancer survivors, many physicians and patients remain concerned about a potential risk of pregnancy specifically in the case of hormone receptor-positive breast cancer. MATERIALS AND
methodsA systematic literature search of Medline, Embase and Cochrane library with no language or date restriction up to 31 March 2023 was carried out. To be included, articles had to be retrospective and prospective case-control and cohort studies as well as clinical trials comparing survival outcomes of premenopausal women with or without a pregnancy after prior diagnosis of hormone receptor-positive breast cancer. Disease-free survival (DFS) and overall survival (OS) were the outcomes of interest. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. Study protocol is registered in PROSPERO (n. CRD42023394232).
resultsOut of 7796 screened studies, 8 were eligible to be included in the final analysis. A total of 3805 patients with hormone receptor-positive invasive early breast cancer were included in these studies, of whom 1285 had a pregnancy after breast cancer diagnosis. Median follow-up time ranged from 3.8 to 15.8 years and was similar in the pregnancy and non-pregnancy cohorts. In three studies (n = 987 patients) reporting on DFS, no difference was observed between patients with and those without a subsequent pregnancy (HR 0.96, 95% CI 0.75-1.24, P = 0.781). In the six studies (n = 3504 patients) reporting on OS, patients with a pregnancy after breast cancer had a statistically significant better OS than those without a pregnancy (HR 0.46, 95% CI 0.27-0.77, P < 0.05).
conclusionsThis systematic review and meta-analysis of retrospective cohort studies provides updated evidence that having a pregnancy in patients with prior history of hormone receptor-positive invasive early breast cancer appears safe without detrimental effect on prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.